Short Peptides Boost Brain's Hypoxia Resistance, Pinealon Leads the Way

Hypoxia, a condition of insufficient oxygen supply, is a major threat to vital organs, especially the brain. It can lead to severe neuronal damage, cognitive impairment, and long-term neurological deficits, particularly in vulnerable populations like newborns experiencing perinatal asphyxia or individuals suffering from stroke. Current therapeutic options for mitigating hypoxic injury are often limited and can have significant side effects. Therefore, there is a critical need for novel strategies to protect cells from oxygen deprivation. This study specifically addresses the knowledge gap regarding the antihypoxic properties of short regulatory peptides and their underlying mechanisms.

All four short regulatory peptides—Vilon, Epitalon, Vesugen, and Pinealon—demonstrated significant antihypoxic properties in the hypobaric hypoxia model. Among these, Pinealon (Glu-Asp-Arg) exhibited the most pronounced antihypoxic effect, substantially increasing neuronal resistance to hypoxic stress, particularly evident in experiments involving prenatal hypoxia. The mechanism of Pinealon's neuroprotective action was complex: it was found to be based not primarily on the direct inhibition of reactive oxygen species (ROS, unstable molecules that can damage cells) increase in cells in response to stress, but rather on the stimulation of the internal antioxidative enzyme system, including enzymes like Glutathione Peroxidase and Superoxide Dismutase. Furthermore, Pinealon possibly contributed to limiting the excitotoxic effect of N-methyl-D-aspartate (NMDA) receptors, which are known to play a role in neuronal damage during hypoxia.